Open AccessIbrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
Author(s) -
Sanjay Varikuti,
Bhawana Singh,
Greta Volpedo,
Dinesh K. Ahirwar,
Bijay Kumar Jha,
Noushin Saljoughian,
Agostinho Gonçalves Viana,
Chaitenya Verma,
Omar Hamza,
Gregory Halsey,
Erin A. Holcomb,
Ritvik Maryala,
Steve Oghumu,
Ramesh K. Ganju,
Abhay R. Satoskar
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0743-8
Subject(s) - ibrutinib , cancer research , bruton's tyrosine kinase , metastasis , breast cancer , medicine , cancer , tyrosine kinase , cancer cell , immunology , chronic lymphocytic leukemia , leukemia , receptor
Ibrutinib is a Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment and metastasis of breast cancer is unclear.